絞り込み

16735

広告

京大霊長類研の教授ら4人 5億円余を不正支出 大学が報告書 (NHK)

サルの研究で世界的に有名な京都大学霊長類研究所の教授ら4人が、研究費5億円余りを不正に支出していたとする調査報告書を京都大学がまとめたことが分かりました。 研究...

  1. ノーベル賞受賞の物性物理の泰斗、アンダー...
  2. ノーベル賞受賞の物性物理の泰斗、アンダー...
  3. 海底の岩、人間の腸内並み微生物 (デイリ...
  4. 新型コロナウイルス感染症の患者等の発生に...

ニュース一覧

A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2.

著者 Vachon CM , Schaid DJ , Ingle JN , Wickerham DL , Kubo M , Mushiroda T , Goetz MP , Carlson EE , Paik S , Wolmark N , Nakamura Y , Wang L , Weinshilboum R , Couch FJ
Breast Cancer Res Treat.2015 Jan 10 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (9,702view , 2users)

Full Text Sources

Medical

Miscellaneous

Molecular Biology Databases

Recent genetic studies have identified common variation in susceptibility loci that stratify lifetime risks of breast cancer and may inform prevention and screening strategies. However, whether these loci have similar implications for women treated with tamoxifen or raloxifene (SERMs) is unknown. We conducted a matched case-control study of 592 cases who developed breast cancer and 1,171 unaffected women from 32,859 participants on SERM therapy enrolled on NSABP P-1 and P-2 breast cancer prevention trials. We formed a quantitative polygenic risk score (PRS) using genotypes of 75 breast cancer-associated single nucleotide polymorphisms and examined the PRS as a risk factor for breast cancer among women treated with SERMs. The PRS ranged from 3.98 to 7.74, with a one-unit change associated with a 42 % increase in breast cancer (OR = 1.42; P = 0.0002). The PRS had a stronger association with breast cancer among high-risk women with no first-degree family history (OR = 1.62) compared to those with a positive family history (OR = 1.32) (P intx = 0.04). There was also suggestion that PRS was a stronger risk factor for ER-positive (OR = 1.59, P = 0.0002) than ER-negative (OR = 1.05, P = 0.84) breast cancer (P intx = 0.10). Associations did not differ by tamoxifen or raloxifene treatment, age at trial entry, 5-year predicted Gail model risk or other clinical variables. The PRS is a strong risk factor for ER-positive breast cancer in moderate to high-risk individuals treated with either tamoxifen or raloxifene for cancer prevention. These data suggest that common genetic variation informs risk of breast cancer in women receiving SERMs.
PMID: 25575444 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード